Takeda Pharmaceutical Reports Revenue Growth in April–June 2026 Quarter, Boosted by Overseas Sales on Weaker Yen

EarningsDigital Finance
โดย 時事通信·Read original
Summary · why it matters

Takeda Pharmaceutical posted higher revenue and operating profit in its consolidated results for the April–June 2026 quarter. The main driver was an expansion in overseas sales due to the weaker yen. The figures are based on International Financial Reporting Standards, though detailed numbers have not been disclosed.

Impact on stocks 1

Biotech & Genomic Medicine▲ · 1 stocks
© 2026 MarketDXNews